Form D · Biotechnology
Holobiome, Inc.
Boston, MA · CIK 0001763027
Offering snapshot reported Jul 22, 2026 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2026 | Initial | $10,000,000 | No comparison | 5 | SEC filing |
| Mar 20, 2024 | Initial | $6,590,554 | No comparison | 19 | SEC filing |
| Feb 11, 2021 | Initial | $300,000 | No comparison | 2 | SEC filing |
| Dec 28, 2018 | Initial | $625,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-591760
Simple Agreement for Future Equity (SAFES)
Source: Form D, filed Jul 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Iain Chessell | Director |
| Ian Chessell | Director |
| Michael Lafleur | Director |
| Michael La Fleur | Executive |
| Joan La Rovere | Director |
| Kim Lewis | Director |
| Philip Strandwitz | Director, Executive |
| Phil Strandwitz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
650 Albany Street Ste 127
Boston, MA, 02118
Phone: (857) 244-1633
Boston, MA, 02118
Phone: (857) 244-1633